The University of Texas MD Anderson Cancer Center
Departments of Thoracic/Head and Neck Medical Oncology and Genomic Medicine
Dr. Zhang is a physician-scientist with lab research focusing in lung cancer genomics and immunogenomics, particularly molecular evolution (from normal lung to premalignancy, to invasive lung cancer, and to metastatic lung cancers), tumor heterogeneity and T cell repertoire of lung cancers and associated impact on cancer biology and clinical outcome. His lab was the first group that reported the genomic heterogeneity (Science. 2014 Oct 10;346(6206):256-9. doi: 10.1126/science.1256930, PMID: 25301631; Nat Commun. 2016 Oct 21;7:13200. doi: 10.1038/ncomms13200. PMID: 27767028), T cell receptor heterogeneity (Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. PMID: 28733428), methylation heterogeneity (Oncotarget. 2017 Mar 28;8(13):21994-22002. doi: 10.18632/oncotarget.15777. PMID: 28423542) and gene expression heterogeneity (Mod Pathol. 2018 Jun;31(6):947-955. doi: 10.1038/s41379-018-0029-3. PMID: 29410488) of lung cancers and demonstrated that complex molecular heterogeneity is associated with complex T cell repertoire and increased risk of postsurgical recurrence. His group has also established approaches to investigate subclonal architecture of lung cancers using circulating tumor DNA (Nat Commun. In press).
Education & Training
M.D. - Tongji Medical University - 1997
Ph.D. - Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College - 2002